About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

At the Paris motor show SERES said AITO will enter European markets next autumn; SERES A-shares hit the daily trading limit. Overseas AITO models will use a "Bosch Inside" co-development model with Bosch; M6–M9 models will be equipped with Bosch’s fu

2026-10-20

At the Paris motor show SERES said AITO will enter European markets next autumn; SERES A-shares hit the daily trading limit. Overseas AITO models will use a "Bosch Inside" co-development model with Bosch; M6–M9 models will be equipped with Bosch’s full intelligent stack covering advanced driver assistance, smart cockpit and chassis. Bosch has started development and plans to begin mass production of highway NOA in September next year.

Other News
2026-10-20

China's National Development and Reform Commission (NDRC) launched on Oct. 20 the first batch of 136 flagship application-scenario projects to steer scenario development and open access. NDRC spokesman Li Chao said the projects have three core tasks:

China's National Development and Reform Commission (NDRC) launched on Oct. 20 the first batch of 136 flagship application-scenario projects to steer scenario development and open access. NDRC spokesman Li Chao said the projects have three core tasks: verification — accelerate maturation and commercial deployment of new technologies, products and business models; openness — enable diverse market participants to share development opportunities; and demonstration — provide templates for wider adoption. As an example, verification scenarios for brain‑computer interfaces will span diagnosis, treatment, assistive and consumer applications and will finance construction of a BCI data platform, pilot-scale testing platform and scenario application centers to support firms' product validation and market expansion.
2026-10-20

China's National Medical Products Administration (NMPA) on Oct. 19 met to advance its AI + drug regulation agenda, directing regulators to set rules, steady expectations, enhance services and build an AI-enabled ecosystem to support pharmaceutical in

China's National Medical Products Administration (NMPA) on Oct. 19 met to advance its AI + drug regulation agenda, directing regulators to set rules, steady expectations, enhance services and build an AI-enabled ecosystem to support pharmaceutical innovation. The NMPA said it will draft special plans to back priority tracks, shift review services upstream toward innovators, and create an innovation-encouraging yet prudently risk-aware regulatory environment; it called for using AI to improve drug-safety governance—making smarter, inspections and enforcement more precise, risk controls more reviews sensitive and coordinated supervision more efficient—and for establishing a full-lifecycle, continuously iterated AI application management mechanism, centralizing resources, training specialist talent, promoting technology-for-good and safeguarding AI security standards.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.